The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population
Open Access
- 7 January 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 22
Abstract
Neuroendocrine cervical carcinoma (NECC) is a rare but aggressive form of cervical cancer representing less than 3% of all cervical cancer cases. The objective of this study is to evaluate the effects of the clinicopathologic features and treatment modalities on the survival of patients with NECC. In all, 89 stage I-IV patients with NECC that were diagnosed and treated between 2006 and 2014 at the Zhejiang Cancer Hospital were retrospectively recruited in this study. The Kaplan-Meier method, Cox regression analysis models and the log-rank test were used for the statistical analyses. NECC patients with advanced FIGO stage, tumor size > 4 cm, lymph node metastasis (LNM) and lymph-vascular space invasion (LVSI) were more likely to have significantly worse survival. Neither neo-adjuvant chemotherapy (NACT) nor radiotherapy (RT) was associated with improved overall survival. In the stratified analysis of stage I-IIA patients, those with advanced FIGO stage (P = 0.018), LNM (P = 0.008) and LVSI (P = 0.024) were associated with significantly worse survival. Patients without LNM who did not receive RT had significantly better survival rates than those who received RT (HR = 3.363, 95%CI = 1.245–10.619; P = 0.018). Moreover, for stage I-IIA patients with tumor size > 4 cm, NACT was not associated with a significantly better survival rate compared with no NACT (P = 0.600). None of the clinicopathologic features or treatment modalities was an independent prognostic factor in the multivariate analysis. In conclusion, advanced FIGO stage, tumor size > 4 cm, LNM and LVSI were associated with poor survival. For stage I-IIA patients, RT should be carefully used in patients who are negative for LNM, and NACT may not be the optimal treatment for patients with tumor size > 4 cm.Keywords
This publication has 12 references indexed in Scilit:
- The local treatment modalities in FIGO stage I‐II small‐cell carcinoma of the cervix are determined by disease stage and lymph node statusCancer Medicine, 2016
- Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patientsBMC Cancer, 2014
- Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical documentGynecologic Oncology, 2011
- Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patientsAmerican Journal of Obstetrics and Gynecology, 2010
- Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution ExperienceJapanese Journal of Clinical Oncology, 2008
- Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean studyAnnals of Oncology, 2007
- Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinomaGynecologic Oncology, 2003
- Prognostic factors in neuroendocrine small cell cervical carcinomaCancer, 2003
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997